PE491A1 - NOVEL ORAL GALLENIC FORM THAT IMPROVES BIOAVAILABILITY - Google Patents

NOVEL ORAL GALLENIC FORM THAT IMPROVES BIOAVAILABILITY

Info

Publication number
PE491A1
PE491A1 PE1990173269A PE17326990A PE491A1 PE 491 A1 PE491 A1 PE 491A1 PE 1990173269 A PE1990173269 A PE 1990173269A PE 17326990 A PE17326990 A PE 17326990A PE 491 A1 PE491 A1 PE 491A1
Authority
PE
Peru
Prior art keywords
novel oral
improves bioavailability
active element
gallenic
gallenic form
Prior art date
Application number
PE1990173269A
Other languages
Spanish (es)
Inventor
Jean-Marc Aiache
Denis Besancon
Original Assignee
Laboratoires Delagrange
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Delagrange filed Critical Laboratoires Delagrange
Publication of PE491A1 publication Critical patent/PE491A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

BUSCA LA MEJORA DE LA DISPONIBILIDAD BIOLOGICA DE UN MEDICAMENTO TRATANDO QUE; CON UNA SOLA TOMA AL DIA, SE LOGRE LIBERAR EL ELEMENTO ACTIVO EN FORMA PROGRESIVA DURANTE LAS SIGUIENTES 24 HORAS, Y AL MISMO TIEMPO BUSCANDO UN MAXIMO APROVECHAMIENTO DE ESTE ELEMENTO ACTIVO. SE LOGRA ESTO, DE ACUERDO CON LO QUE SE SOLICITA, POR LA PRESENCIA EN LA FORMULACION DE PROTEINAS NATURALES, EN ESPECIAL LAS DERIVADAS DE LA LECHE DESNATADA. SE HACE DE ESTE SISTEMA A PASTILLAS QUE CONTIENE PRINCIPIOS INHIBIDORES DEL CALCIO, TALES COMO LA DIHIDROPIRIDINA, LA OXODIPINA Y LA NIFEDIPINASEEKS TO IMPROVE THE BIOLOGICAL AVAILABILITY OF A MEDICATION BY TREATING THAT; WITH A SINGLE TAKE A DAY, IT IS POSSIBLE TO RELEASE THE ACTIVE ELEMENT IN A PROGRESSIVE FORM FOR THE FOLLOWING 24 HOURS, AND AT THE SAME TIME SEEKING A MAXIMUM USE OF THIS ACTIVE ELEMENT. THIS IS ACHIEVED, IN ACCORDANCE WITH WHAT IS REQUESTED, BY THE PRESENCE IN THE FORMULATION OF NATURAL PROTEINS, ESPECIALLY THE DERIVATIVES OF SKIMMED MILK. THIS SYSTEM IS MADE TO PILLS CONTAINING CALCIUM INHIBITING PRINCIPLES, SUCH AS DIHYDROPYRIDINE, OXODIPINE AND NIFEDIPINE

PE1990173269A 1989-08-07 1990-08-03 NOVEL ORAL GALLENIC FORM THAT IMPROVES BIOAVAILABILITY PE491A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8910605A FR2650502B1 (en) 1989-08-07 1989-08-07 NEW ORAL GALENIC FORM IMPROVING BIOAVAILABILITY

Publications (1)

Publication Number Publication Date
PE491A1 true PE491A1 (en) 1991-01-26

Family

ID=9384532

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1990173269A PE491A1 (en) 1989-08-07 1990-08-03 NOVEL ORAL GALLENIC FORM THAT IMPROVES BIOAVAILABILITY

Country Status (25)

Country Link
EP (1) EP0412877A1 (en)
JP (1) JPH0377819A (en)
KR (1) KR910004181A (en)
CN (1) CN1049455A (en)
AU (1) AU631235B2 (en)
CA (1) CA2022447A1 (en)
CS (1) CS383890A3 (en)
DD (1) DD297332A5 (en)
DE (1) DE4023136A1 (en)
FI (1) FI903885A0 (en)
FR (1) FR2650502B1 (en)
GB (1) GB2234898A (en)
HU (1) HU204997B (en)
IE (1) IE902629A1 (en)
IL (1) IL95105A0 (en)
IN (1) IN170789B (en)
LU (1) LU87777A1 (en)
MA (1) MA21923A1 (en)
NO (1) NO903442L (en)
NZ (1) NZ234593A (en)
OA (1) OA09301A (en)
PE (1) PE491A1 (en)
PT (1) PT94823A (en)
TN (1) TNSN90111A1 (en)
ZA (1) ZA905886B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679906B2 (en) * 1992-01-17 1997-07-17 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
DE4221880A1 (en) * 1992-07-03 1994-01-05 Alfatec Pharma Gmbh Solid and liquid solutions of poorly water-soluble drugs
KR20030089147A (en) * 2002-05-16 2003-11-21 슈라펫 주식회사 Water bottle for pet

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE854414C (en) * 1949-04-26 1952-11-04 Dieter Dr Med Ellenbeck Process for the production of injectable solutions of more or less poorly soluble medicaments
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB906422A (en) * 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
US3015611A (en) * 1959-08-25 1962-01-02 Nysco Lab Inc Low density whey-bound tablets
GB1063872A (en) * 1962-08-11 1967-03-30 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical compositions
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE3200766A1 (en) * 1981-01-14 1982-09-16 Toyo Jozo Kk Product with excellent absorption property
FR2524312B1 (en) * 1982-04-01 1985-10-04 Tech Cuir Centre NOVEL FORMS OF MICRO-ENCAPSULATION OF DRUG SUBSTANCES BY HOMOGENEOUS LAYERS OF NATIVE COLLAGEN
JPS59101423A (en) * 1982-12-02 1984-06-12 Takada Seiyaku Kk Novel solid pharmaceutical preparation of nifedipine
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
US4670251A (en) * 1984-05-30 1987-06-02 Igene Biotechnology, Inc. Microcrystalline tableting excipient derived from whey
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
DE3702105A1 (en) * 1987-01-24 1988-08-04 Bayer Ag PARENTERAL SOLUTION
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
CA1324083C (en) * 1987-03-09 1993-11-09 Tetsu Miyoshi Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
DK179687D0 (en) * 1987-04-08 1987-04-08 Farma Food As PREPARATION
ATE90205T1 (en) * 1987-09-08 1993-06-15 Takeda Chemical Industries Ltd WATER-INSOLUBLE CYTOKINS.

Also Published As

Publication number Publication date
FR2650502A1 (en) 1991-02-08
HU904909D0 (en) 1991-01-28
NZ234593A (en) 1993-04-28
FR2650502B1 (en) 1994-05-27
OA09301A (en) 1992-09-15
HUT55230A (en) 1991-05-28
IN170789B (en) 1992-05-23
IE902629A1 (en) 1991-02-27
AU631235B2 (en) 1992-11-19
JPH0377819A (en) 1991-04-03
GB9017144D0 (en) 1990-09-19
CS276556B6 (en) 1992-06-17
CS383890A3 (en) 1992-06-17
AU6023990A (en) 1991-02-07
LU87777A1 (en) 1990-12-11
KR910004181A (en) 1991-03-28
DE4023136A1 (en) 1991-02-14
CA2022447A1 (en) 1991-02-08
ZA905886B (en) 1991-04-24
IL95105A0 (en) 1991-06-10
DD297332A5 (en) 1992-01-09
HU204997B (en) 1992-03-30
FI903885A0 (en) 1990-08-06
EP0412877A1 (en) 1991-02-13
GB2234898A (en) 1991-02-20
NO903442D0 (en) 1990-08-06
PT94823A (en) 1991-04-18
NO903442L (en) 1991-02-08
TNSN90111A1 (en) 1991-03-05
MA21923A1 (en) 1991-04-01
CN1049455A (en) 1991-02-27

Similar Documents

Publication Publication Date Title
ES2181723T3 (en) PHARMACEUTICAL FORMULATIONS OF NERVOUS GROWTH FACTOR.
PT1200105E (en) FACTOR VIII MODIFIED
DE3872372D1 (en) COMPOSITION FOR INCREASING INTRA-CELL-ATP LEVELS AND PHYSICAL PERFORMANCE LEVELS AND FOR INCREASING THE SPEED OF Wounds Healing.
DE68923819D1 (en) Use of gamma-hydroxy butyric acid salts for the manufacture of pharmaceutical compositions for use in the treatment of alcoholism and the compositions prepared.
BR9801126A (en) 1,4-benzothiazepine-1,1-hypolipidemic dioxides.
MX9203543A (en) MEDICINE.
ATE73331T1 (en) USE OF TETRAHYDROBIOPTERINS TO MANUFACTURE A MEDICATION FOR THE TREATMENT OF CHILDREN'S AUTISM.
ES2070919T3 (en) CHROMATOGRAPHIC SEPARATION OF PLASMA PROTEINS, MAINLY FACTOR VIII, WILLEBRAND FACTOR OF FIBRONECTIN AND FIBRINOGEN.
DE59102210D1 (en) Pharmaceutical formulation containing galanthemin for the treatment of alcoholism.
ES2044925T3 (en) PHARMACEUTICAL COMPOSITIONS OF DELAYED RELEASE.
ATE103812T1 (en) COMPOSITION FOR THE TREATMENT OF ISCHEMIC DISORDERS IN ORGANS.
ES2052583T3 (en) DERIVATIVES OF PEPTIDES RELATED TO THE CALCITONIN GEL.
ATE85523T1 (en) TAUROHYODEOXYCHOLIC ACID FOR THE TREATMENT OF Biliary Stones and Biliary Disorders.
ES2133295T3 (en) CYCLIC PEPTIDES AND THEIR USE.
PE491A1 (en) NOVEL ORAL GALLENIC FORM THAT IMPROVES BIOAVAILABILITY
DE3781686D1 (en) COMPOSITION CONTAINING FATTY ACID AND CYCLOSPORINE WITH REDUCED NEPHROTOXICITY.
DK0840748T3 (en) Transforming growth factor beta crystals
MX9301535A (en) BIOLOGICALLY ACTIVE PROTEINACEOUS MATERIAL ISOLATED AND PURIFIED.
ATE110723T1 (en) GASGASIC ACID INHIBITOR COMPOUNDS AND METHOD OF PREPARATION.
ATE160090T1 (en) USE OF L-CARNITINE AND ACYL-L-CARNITINE FOR THE TREATMENT OF PATIENTS SUFFERING FROM AIDS-RELATED SYNDROMES AND ASYMPTOMATIC HIV SEROPOSITIVE PATIENTS
MX9300638A (en) DERIVATIVES OF AMINOBENZOIC ACID.
DK592988A (en) PHARMACEUTICALS, CONTAINING PHOSPHOROUS 2-ISOXAZOLINES AND ISOXAZOLES, AND THE PREPARATION OF THESE HETEROCYCLIC COMPOUNDS
ATE80036T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN 8-CHLORO-BENZOTHIAZEPINE COMPOUND AND ITS USE.
IT1222414B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TRAPIDIL, THEIR PREPARATION PROCEDURE AND RELATED THERAPEUTIC USE
ATE59038T1 (en) TAURINE DERIVATIVE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.